Form 4: Clene Inc. Director Jacobovitz Shalom Acquires Stock Options

Director Jacobovitz Shalom was granted options to purchase 50,135 shares of Clene Inc. common stock at an exercise price of $0.37 per share.

Summary

• On June 7, 2024, Jacobovitz Shalom, a director of Clene Inc., was granted stock options to purchase 50,135 shares of the company's common stock.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• The exercise price for the options is $0.37 per share.
• The options vest immediately upon grant and expire on June 6, 2034.
• Following the transaction, Jacobovitz Shalom directly owns options for 50,135 shares of Clene Inc. common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain any overtly positive or negative information. It's a neutral event from an investment perspective.

Positives

• The immediate vesting of the options suggests confidence in the director's continued contribution to the company.
• The grant of stock options aligns the director's interests with those of the shareholders.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences routinely grant stock options to their directors and officers as part of their overall compensation packages.
• The vesting schedules and exercise prices of these options vary depending on the company's performance and the individual's role.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates